Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy

Background/Aim: Liver biopsy has so far been the only method to accurately follow the progression of primary biliary cirrhosis (PBC). The stage and the severity of lymphocytic piecemeal necrosis (LPN) have been shown to be an independent factor for the development of cirrhosis. In this 3‐year prospective study, we evaluated the diagnostic value of several liver function tests, surrogate markers of fibrogenesis, hyaluronic acid (HA), procollagen III N‐terminal peptide (S‐PIIINP), cholestanol and plant sterols in noncirrhotic PBC patients treated with ursodeoxycholic acid (UDCA) or with UDCA and budesonide to assess the stage, inflammation and fibrosis.

[1]  Patrice Faure,et al.  Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.

[2]  M. Sorrell,et al.  Noninvasive tests for liver fibrosis. , 2006, Seminars in liver disease.

[3]  E. Björnsson,et al.  The AST/ALT ratio as an indicator of cirrhosis in patients with PBC , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[4]  D. Rockey,et al.  Noninvasive measures of liver fibrosis , 2006, Hepatology.

[5]  M. Färkkilä,et al.  Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.

[6]  H. Isoniemi,et al.  Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[8]  Y. Chrétien,et al.  Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA‐treated patients with primary biliary cirrhosis , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[9]  A. Chetwynd,et al.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort , 2004, Gut.

[10]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[11]  K. Lindor,et al.  Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. , 2003, Journal of hepatology.

[12]  T. Sudhop,et al.  Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion , 2002, Gut.

[13]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[14]  F. Carrat,et al.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. , 2002, Gastroenterology.

[15]  F. Carrat,et al.  The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis , 2000, Hepatology.

[16]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[17]  M. Färkkilä,et al.  Serum cholestanol, cholesterol precursors, and plant sterols during placebo‐controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine , 1995, Hepatology.

[18]  M. Färkkilä,et al.  Other clinical studySerum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine☆ , 1995 .

[19]  J. Boyer,et al.  Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. , 1995, Journal of Hepatology.

[20]  B. Balkau,et al.  Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. , 1994, The New England journal of medicine.

[21]  E. Dickson,et al.  Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. , 1994, Gastroenterology.

[22]  A. West,et al.  A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1993, Hepatology.

[23]  M. Kaplan,et al.  Primary Biliary Cirrhosis , 1987, The New England journal of medicine.

[24]  J. Boyer,et al.  Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. , 1985, Gastroenterology.

[25]  J. Boyer,et al.  Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. , 1985, Gastroenterology.

[26]  T. Miettinen,et al.  Gas-liquid chromatographic determination of fecal neutral sterols using a capillary column. , 1982, Clinica chimica acta; international journal of clinical chemistry.

[27]  E. Dickson,et al.  Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) , 1978, Virchows Archiv A.

[28]  Anand K. Srivastava,et al.  Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption , 2001, Nature Genetics.

[29]  L. Rodrigo,et al.  Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. , 2000, Journal of hepatology.

[30]  T. Therneau,et al.  Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. , 1999, Hepatology.

[31]  A. Nyberg,et al.  Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. , 1989, Scandinavian journal of gastroenterology.